PDS Biotechnology Corporation (PDSB), a clinical-stage biotechnological company specializing to develop unique cancer therapies centered on the PDSB proprietary Versamune T-cell activating technology, announced the publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). PDSB stock price surged adjacent to the news.
At last check-in premarket trading, shares of PDS Biotechnology Corporation (PDSB) were up 4.58% at $8.71. PDSB’s stock closed the last session at $8.33, increasing 14.58% or $1.06. Shares of the company fluctuated between $6.80 and $8.64 throughout the day. The shares of PDS Biotechnology Corporation have advanced 75.00% in the last five days; however, they have gained 55.12% over the last month.
The abstract outlining interim data and information from the National Cancer Institute (NCI)-headed phase 2 trial has been approved for oral presentation at the 2021 ASCO Annual Meeting happening from June 4-8. The presentation, set on June 7th, is anticipated to be inclusive of results from a bigger sample compared to the 14 patients from the abstract.
Additional data from abstract #2501 was inclusive of:
A general objective response concluded 71% (10/14) in patients affected with refractory HPV16-associated cancers
1 complete response produced, anal cancer.
9 partial responses produced inclusive of 3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer.
90% of these responses are continued after an average 5 months of checking and follow-up.
The NCI Center for Cancer Research’s Laboratory of Tumour Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are mutually directing this Phase 2 trial (NCT04287868), which emphasize on PDS0101 combined with two investigational immune-modulating chemicals: bintrafusp alfa (M7824), a bifunctional “trap” fusion protein targeting TGF-β and PD-L1, and NHS-IL12 (M9241), a tumor-specific immunocytokine.
The trial is assessing the combination formed for treatment in both checkpoint inhibitor naïve and refractory patients with high-stage human papillomavirus (HPV)-linked cancers that have advanced or have come back after treatment.
There are cases exceeding 630,000 of HPV-associated malignancies inclusive of cervical, oropharyngeal, and anal cancer globally per annum. HPV 16 is responsible for majority of the cases. About 15-20% of HPV-linked malignancies are countered by PD-(L)1 inhibitors. However, for most of the patients who advance on these immunotherapies, there is no efficient standard of care therapy.
Positive data concluded from the studies which may potentially depict an objective response against cancer has been deemed extremely significant for the medical society and has induced investor interest, with PDSB stock price rising at last check.